| Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator‐initiated, multicenter, double‐blind, randomized, placebo‐controlled trial D Khanna, C Spino, S Johnson, L Chung, ML Whitfield, CP Denton, ... Arthritis & rheumatology 72 (1), 125-136, 2020 | 191 | 2020 |
| Embryo-scale, single-cell spatial transcriptomics SR Srivatsan, MC Regier, E Barkan, JM Franks, JS Packer, P Grosjean, ... Science 373 (6550), 111-117, 2021 | 162 | 2021 |
| Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile B Skaug, D Khanna, WR Swindell, ME Hinchcliff, TM Frech, VD Steen, ... Annals of the rheumatic diseases 79 (3), 379-386, 2020 | 124 | 2020 |
| Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double‐blind, placebo‐controlled, pilot trial JK Gordon, V Martyanov, JM Franks, EJ Bernstein, J Szymonifka, C Magro, ... Arthritis & rheumatology 70 (2), 308-316, 2018 | 124 | 2018 |
| A Machine Learning Classifier for Assigning Individual Patients with Systemic Sclerosis to Intrinsic Molecular Subsets JM Franks, V Martyanov, G Cai, Y Wang, Z Li, TA Wood, ML Whitfield Arthritis & Rheumatology, 2019 | 68 | 2019 |
| Feature specific quantile normalization enables cross-platform classification of molecular subtypes using gene expression data JM Franks, G Cai, ML Whitfield Bioinformatics 34 (11), 1868-1874, 2018 | 64 | 2018 |
| Mycophenolate mofetil treatment of systemic sclerosis reduces myeloid cell numbers and attenuates the inflammatory gene signature in skin M Hinchcliff, DM Toledo, JN Taroni, TA Wood, JM Franks, MS Ball, ... Journal of Investigative Dermatology 138 (6), 1301-1310, 2018 | 60 | 2018 |
| Machine learning predicts stem cell transplant response in severe scleroderma JM Franks, V Martyanov, Y Wang, TA Wood, A Pinckney, LJ Crofford, ... Annals of the rheumatic diseases 79 (12), 1608-1615, 2020 | 42* | 2020 |
| Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skin ME Johnson, JM Franks, G Cai, BK Mehta, TA Wood, K Archambault, ... Arthritis research & therapy 21, 1-11, 2019 | 29 | 2019 |
| Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement K Showalter, R Spiera, C Magro, P Agius, V Martyanov, JM Franks, ... Annals of the rheumatic diseases 80 (2), 228-237, 2021 | 24 | 2021 |
| BioMethyl: an R package for biological interpretation of DNA methylation data Y Wang, JM Franks, ML Whitfield, C Cheng Bioinformatics 35 (19), 3635-3641, 2019 | 22 | 2019 |
| A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis JM Franks, DM Toledo, V Martyanov, Y Wang, S Huang, TA Wood, ... Rheumatology 62 (1), 19-28, 2023 | 6 | 2023 |
| Single-cell analysis of chromatin and expression reveals age-and sex-associated alterations in the human heart DF Read, G Booth, RM Daza, DL Jackson, RG Gladden, SR Srivatsan, ... BioRxiv, 2022.07. 12.496461, 2022 | 6 | 2022 |
| Regulator combinations identify systemic sclerosis patients with more severe disease Y Wang, JM Franks, M Yang, DM Toledo, TA Wood, M Hinchcliff, ... JCI insight 5 (17), 2020 | 5 | 2020 |
| Clinical and molecular findings after autologous stem cell transplantation or cyclophosphamide for scleroderma: handling missing longitudinal data L Keyes‐Elstein, A Pinckney, E Goldmuntz, B Welch, JM Franks, ... Arthritis Care & Research 75 (2), 307-316, 2023 | 4 | 2023 |
| Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebocontrolled, pilot trial. Arthritis Rheumatol (Hoboken, NJ). 2018 … JK Gordon, V Martyanov, JM Franks, EJ Bernstein, J Szymonifka, C Magro | 4 | |
| Pulmonary osteoclast-like cells in silica induced pulmonary fibrosis Y Hasegawa, JM Franks, Y Tanaka, Y Uehara, DF Read, C Williams, ... bioRxiv, 2023 | 2 | 2023 |
| Machine-learning classification identifies early systemic sclerosis patients that improve with abatacept treatment by modulating CD28-pathways BK Mehta, ME Espinoza, JM Franks, Y Yuan, Y Wang, T Wood, ... JCI Insight 7 (24), e155282, 2022 | 2 | 2022 |
| Abatacept in early diffuse cutaneous systemic sclerosis: results of a Phase II investigator-initiated, multicenter, double-blind, randomized. placebo-controlled trial … D Khanna, C Spino, S Johnson, L Chung, ML Whitfield, CP Denton, ... | 2 | 2020 |
| Machine-learning classification identifies patients with early systemic sclerosis as abatacept responders via CD28 pathway modulation BK Mehta, ME Espinoza, JM Franks, Y Yuan, Y Wang, T Wood, ... JCI insight 7 (24), 2022 | 1 | 2022 |
Michael L. Whitfield, PhDChair and Professor of Biomedical Data Science, Geisel School of Medicine at DartmouthПодтвержден адрес электронной почты в домене dartmouth.edu
